Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0012 | 0.0593 | 0.0649 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.004 | 0.8151 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.9136 | 0.9136 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0012 | 0.0593 | 0.0593 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.9136 | 0.9136 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.9136 | 0.5 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Echinococcus multilocularis | voltage gated potassium channel | 0.0012 | 0.0593 | 0.0649 |
Echinococcus granulosus | voltage gated potassium channel | 0.0012 | 0.0593 | 0.0649 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0043 | 0.8923 | 0.9766 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.9136 | 0.5 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.001 | 0 | 0.5 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0012 | 0.0593 | 0.0649 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Brugia malayi | hypothetical protein | 0.0043 | 0.9136 | 1 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0043 | 0.8923 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0012 | 0.0593 | 0.0593 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Schistosoma mansoni | voltage-gated potassium channel | 0.0047 | 1 | 1 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0043 | 0.8923 | 0.9766 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.9136 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.9136 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0593 | 0.0664 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.7374 | 0.8264 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0012 | 0.0593 | 0.0649 |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.001 | 0 | 0.5 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0043 | 0.8923 | 0.9766 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.9136 | 1 |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Onchocerca volvulus | 0.001 | 0 | 0.5 | |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.9136 | 1 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.004 | 0.8151 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 7.3078 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 7.9433 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.